Relay Therapeutics (RLAY) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.41
- Estimate
- -$0.39
- Surprise
- -4.9%
- Revenue (period 2026-06-30)
- $350,000
- Score today
- 4.3/10
Revenue source: xbrl.
How the report landed
Relay Therapeutics (RLAY) reported a wider loss than forecast — adjusted EPS of -$0.41 against the -$0.39 estimate (a 4.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RLAY Sell at 4.3/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -4.9% surprise compares with a -0.2% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: zovegalisib (RLY-2608)
- Quality below floor (1.5 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (8 sells, 4.13% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.28
- Price target
- $24.00
- Stop
- $15.65
- Upside to target
- +47.4%
- Reward-to-risk
- 4.0:1
Model outputs from TrendMatrix’s engine as of 2026-10-16 — shown for context, not personalized investment advice.
RLAY at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.79B
- P/E (fwd)
- -10.6
- 52-week range
- $5.95–$21.27
- Off 52-week high
- 23.5%
- RSI (14)
- 40
- Volume vs avg
- 0.80×
- Score today
- 4.3/10